DOCSLIB.ORG

List of Issuers with No Outstanding Past-Due Share of the Issuer Accounting Support Fee

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Issuers with No Outstanding Past-Due Share of the Issuer Accounting Support Fee 1666 K Street NW Washington, DC 20006 Office: (202) 207-9100 www.pcaobus.org List of Issuers with No Outstanding Past-Due Share of the Issuer Accounting Support Fee Determination of Payment under PCAOB Rule 7104(b) As of December 9, 2019 The following is a list of issuers that have been assessed and have no outstanding past-due share of the issuer accounting support fees of the Public Company Accounting Oversight Board ("PCAOB") and the Financial Accounting Standards Board ("FASB"), as of December 9, 2019.1/ A registered public accounting firm may take the inclusion of an issuer on this list as an indication that the issuer has no outstanding past-due share of the issuer accounting support fee for purposes of PCAOB Rule 7104(b). This list will be updated at least bi-weekly. If a registered public accounting firm cannot obtain a representation from the issuer or cannot determine by reviewing the list below whether the issuer has no past-due share of the accounting support fee outstanding, the registered public accounting firm may contact the staff by phone at 1- 202-207-9294 (Business Days: 9:00 a.m. to 5:00 p.m. ET) or by email at [email protected]. If you believe an issuer has been excluded from this list in error, please contact the staff by phone at 1-202-207-9294 (Business Days: 9:00 a.m. to 5:00 p.m. ET) or by email at [email protected]. 1/ Just because an issuer does not appear on this list does not mean that the issuer has outstanding a past-due share of the accounting support fee. Many "issuers," as that term is defined in the Sarbanes-Oxley Act and the Board's rules, are not allocated a share of the issuer accounting support fee of the PCAOB and the FASB under the Board's funding rules and therefore are not on this list even though they have outstanding no past-due share of the accounting support fee. In addition, payments are received periodically by the PCAOB and are not reflected on this list until it is next updated. For more information regarding the determination of payment of accounting support fees by registered accounting firms, please see rule 7104(b). Public Company Accounting Oversight Board Issuers With No Outstanding Past-Due Share as of December 9, 2019 Additional information about the issuer accounting support fee and the funding process is available in the Frequently Asked Questions ("FAQs") available in the Accounting Support Fee section of the PCAOB's Web site (http://pcaobus.org/About/Administration/SupportFee/Pages/SupportFeeFAQ.aspx). * * * 1290 VT Equity Income A.F.P. Provida Sa AB Muni Income II VA 1290 VT GAMCO Small Co A10 Networks Inc AB Muni Income National Value A123 Systems Inc AB Municipal Income NY 180 CONNECT INC A21 GROUP INC AB Municipal Income Shares 1-800 CONTACTS INC A4S SECURITY INC AB Pooling Bond Inflation 1-800-FLOWERS.COM Inc AAIPHARMA INC Protected 1st Century Bancshares Inc AAM/Bahl & Gaynor Income AB Pooling Global Core Bond 1st Constitution Bancorp Growth AB Pooling High Yield 1st Financial Services Corp AAMES INVESTMENT AB Pooling International 1st Independence Financial CORP Growth Group Inc AAON Inc AB Pooling International 1st Pacific Bancorp AAR CORP Value 1st Source Corp Aaron's Inc AB Pooling Multi Asset Real 1ST ST BANCORP INC AB 2015 Retirement Strategy Return 1st United Bancorp Inc AB 2020 Retirement Strategy AB Pooling Short Duration 21ST CENTURY INS AB 2025 Retirement Strategy Bond GROUP AB 2030 Retirement Strategy AB Pooling Small Mid Cap 21Vianet Group Inc AB All Market Total Return Growth 22nd Century Group Inc AB Conservative Wealth AB Pooling Small Mid Cap 24/7 REAL MEDIA INC Strategy Value 2U Inc AB Discovery Growth AB Pooling US Large Cap 360 GLOBAL WINE CO AB Discovery Value Growth 361 Global Long/Short Equity AB Equity Income AB Pooling US Value 361 Managed Futures AB Global Bond AB Pooling Volatility Strategy AB Global Risk Allocation Management 3COM CORP AB Global Value AB Relative Value 3M Co AB Government Exchange AB Select US Long/Short 3PAR Inc Reserves AB Small Cap Core 3Pea International Inc AB Growth AB Small Cap Growth 4KIDS ENTERTAINMENT AB High Income AB Sustainable Global INC AB High Yield Thematic 51job Inc AB Income AB Tx Mngd Bal Wealth 7 Days Group Holdings Ltd AB International Growth Strategy 724 SOLUTIONS INC AB International Research AB Tx Mngd Wealth Apprec 7-ELEVEN INC Growth AB Value 8point3 Energy Partners LP AB International Small Cap AB VPS Balnced Wealth 8x8 Inc AB International Strategic AB VPS Dynamic Asset 99 Cents Only Stores Equities Allocation A S V INC AB Intl Value AB VPS Global Technology A V Homes Inc AB Large Cap Growth AB VPS Growth & Income A. H. Belo Corp AB Multi Market Strategy AB VPS Intl Value A. O. Smith Corp Trust AB VPS Large Cap Growth A.C. Moore Arts & Crafts Inc AB Muni Income CA AB VPS Small/Mid Cap A.D.A.M. Inc AB Muni Income II FL Value Page 2 Public Company Accounting Oversight Board Issuers With No Outstanding Past-Due Share as of December 9, 2019 AB VPS Value Abington Bancorp Inc Access Flex Bear High Yield AB Wealth Appreciation ABIOMED Inc Access National Corp Abakan Inc ABIS All Market Real Return Access Plans USA Inc ABAXIS Inc Strategy Accessor Small/Mid Cap ABB Ltd ABIS Bond Inflation Acclaim Enmnt Inc Abbey Capital Futures ABIS Municipal Bond Inflation ACCO Brands Corp Strategy Strategy ACCREDITED HOME ABBF Corporate Bond ABITIBI CONSOLIDATED LENDERS HLDG ABBF Intermediate Bond INC Accredited Members Holding ABBF US Government ABLE ENERGY INC Corp Abbott Laboratories ABLE LABORATORIES INC ACCREDO HEALTH INC. ABBSF-Emerging Markets ABLEAUCTIONS.COM INC ACCUPOLL HOLDING AbbVie Inc Ablynx NV CORP Abengoa SA ABM Industries Inc ACCURAY INC Abeona Therapeutics Inc ABMIF High Income Muni Accuride Corp Abercrombie & Fitch Co. ABN AMRO Balanced ACE Avation Holdings Inc Aberdeen Asia Bond ABN AMRO Bond ACE CASH EXPRESS INC Aberdeen Asia Pacific (ex ABN Amro Holding NV ACE COMM CORP Japan) Equity ABN AMRO Investor Money AcelRx Pharmaceuticals Inc Aberdeen Asia-Pacific Mkt Acer Therapeutics Inc Income Fund Inc. ABN AMRO Treasury MM Achillion Pharmaceuticals Inc Aberdeen Australia Equity ABN AMRO TxEx MM ACI Worldwide Inc Fund Inc. Abovenet Inc Aclara Biosciences Inc Aberdeen Emerging Markets Abraxas Petroleum Corp. Aclaris Therapeutics Inc Aberdeen Emerging Markets Abraxis BioScience Inc ACM Institutional MM CA Equity Income Fund Inc Absolute Opportunities ACM Institutional MM Govt Aberdeen Equity Long-Short Absolute Strategies ACM Institutional MM Prime Aberdeen Global High AC Alternatives Market ACM Institutional MM Income Neutral Value Treasury Aberdeen International Equity AC Immune SA ACM Institutional MM Trust Aberdeen Select International ACA CAPITAL HOLDINGS ACM Institutional MM TxFr Equity INC ACM Research Inc Aberdeen Standard Acacia Communications Inc ACME Communications Inc Palladium ETF Trust Acacia Research Corp Acme Packet Inc Aberdeen Standard Platinum Acadia Healthcare Co Inc Acme United Corp ETF Trust Acadia Pharmaceuticals Inc ACNB Corp Aberdeen Standard Precious Acadia Realty Trust Acorda Therapeutics Inc Metals Basket ETF Trust Acadian Emerging Markets Acorn Energy Inc Aberdeen Standard Silver Acambis Plc Acorn International Inc ETF Trust Acasti Pharma Inc ACR GROUP INC Aberdeen Total Return Bond Accelerate Diagnostics Inc Acres Gaming Inc Aberdeen UltraShort Accelerize Inc ACRO INC Municipal Income Acceleron Pharma Inc Across America Real Estate Aberdeen US Small Cap Accelrys Inc. Corp Equity Accentia Biopharmaceuticals ACS-TECH80 LTD Abgenix Inc Inc ACT TELECONFERENCING ABIF-Global REIT Accenture PLC INC Institutional Acceptance Insurance Cos Actel Corp Abigail Adams National Inc Actiga Corp Bancorp Inc Access Capital Community Actinium Pharmaceuticals Inc Ability Inc. Investment Page 3 Public Company Accounting Oversight Board Issuers With No Outstanding Past-Due Share as of December 9, 2019 ACTION PERFORMANCE ADELPHIA COMMUN -CL A Advanced Life Sciences COS INC Adept Technology Inc Holdings Inc Actions Semiconductor Co ADESA INC ADVANCED MARKETING Ltd Adesto Technologies Corp SERVICES Activcard Corp AdEx Media Inc Advanced Medical Optics Inc. Active Assets CA Tax Free ADEZA BIOMEDICAL CORP Advanced Micro Devices Inc MM Adient Plc Advanced Photonix Inc. Active Assets Government Adira Energy Ltd ADVANCED POWER Trust ADMA Biologics Inc TECHNOL INC Active Assets Govt MM Adobe Inc Advanced Tech Industries Active Assets Money ADOLOR CORP Advanced Technology Active Assets Prime Trust Adomani Inc Acquisition Corp Active Assets TxFr MM ADSTAR INC ADVANCED VIRAL Active Health Foods Inc ADT Corp (The) RESEARCH CORP Active Network Inc ADT Inc Advanced Voice Recognition Active Power Inc Adtalem Global Education Inc Systems Inc Activision Blizzard Inc ADTRAN Inc Advancepcs Activision Inc. ADUDDELL INDUSTRIES AdvancePierre Foods Actua Corp INC Holdings Inc Actuant Corp Aduro BioTech Inc AdvanSix Inc Actuate Corp ADV NEUROMODULATION Advanta Corp Acuity Brands Inc. SYS INC Advantage Oil & Gas Ltd ACURA Advance America Cash ADVANTEST CORP PHARMACEUTICALS INC Advance Centers Inc Advantus Srs Asset Acushnet Holdings Corp Advance Auto Parts Inc. Allocation ACUSPHERE INC Advance Capital Balanced Advantus Srs Bond AD VENTURE PARTNERS Advance Capital Retire Advantus Srs Mortgage Sec INC Income Advaxis Inc Adamas Pharmaceuticals Inc ADVANCE NANOTECH INC Advent Claymore Convertible Adamis Pharmaceuticals Advanced Accelerator Securities and Income Fund Corp Applications SA Inc Adams Diversified Equity Advanced Analogic Advent Software Inc. Fund Inc Technologies Inc Advent/Claymore Global Adams Golf Inc. Advanced Battery Convertible Securities & Adams Natural Resources Technologies Inc Income Fund Fund Inc Advanced BioMedical Adverum Biotechnologies Inc Adams Resources & Energy Technologies Inc AdvisorOne CLS Global Inc. ADVANCED BIOTHERAPY Diversified Equity ADAMS RESPIRATORY INC AdvisorOne Milestone THERAPTCS ADVANCED DIGITAL INFO Treasury Obligation Adaptimmune Therapeutics CORP AdvisorShares Peritus High plc Advanced Disposal Services Yield ETF ADC Telecommunications Inc Advisory Board Company Inc.
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Documentation and to Perform a Survey with College Students
    CITY OF PONTIAC, MICHIGAN GENERAL EMPLOYEES RETIREMETN SYSTEM BOARD OF TRUSTEES SPECIAL MEETING FEBRUARY 10, 2010 A special meeting of the Board of Trustees was held on Wednesday, February 10, 2010 at the Shrine Room, Main Level, City Hall, 47450 Woodward Avenue, Pontiac, Michigan 48342. The meeting was called to order at 10:30 a.m. TRUSTEES PRESENT TRUSTEES ABSENT Shirley Barnett Patrice Waterman (absent) Charlie Harrison, Chairman Kevin Williams (absent) Mayor, Leon Jukowski Javier Sauceda, Vice Chair Devin Scott (arrived at 10:38 a.m.) Debra Woods Andrea Wright OTHERS PRESENT Chris Kuhn, Gray & Company Paul Elio, Elio Motors Laurance Gray, Gray & Company Gino Raffin, Elio Motors Ellen Zimmermann, Retirement Administrator Steven Semansky, Elio Motors Deborah Munson, Retirement Accountant Jeff Yager, ABC Group Jane Arndt, M-Administrative Assistant Dave Kesselring, AGS Automotive Kevin Hodgins, Linamar/McClaren Jeff Johnston, Takata Chairman Harrison said that the Board heard a brief overview of the Elio three-wheel car presentation. He asked if Mr. Gray had anything to add. This special meeting of the Board is being held to hear Mr. Elio’s presentation with any decisions being made after the presentation. Re: Elio Motors Presentation – Trikke Project Paul Elio told the Board that he appreciated them coming out on this snowy day. The large entourage that accompanied him includes two members from Elio Motors and the others are their suppliers who also supply parts to General Motors, Ford and Chrysler. It is unusual for an automotive company to include outside folks in their presentation. The suppliers represented today make up 44% of the car base.
    [Show full text]
  • Fibrolase: Trials and Tribulations
    Toxins 2010, 2, 793-808; doi:10.3390/toxins2040793 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Fibrolase: Trials and Tribulations Francis S. Markland 1,2,* and Steve Swenson 1,2 1 Department of Biochemistry and Molecular Biology, Cancer Research Laboratory, Keck School of Medicine, University of Southern California, 1303 N. Mission Rd., Los Angeles, CA 90033, USA 2 USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-(323) 224-7981; Fax: +1-(323) 224-7679. Received: 11 March 2010; in revised form: 31 March 2010 / Accepted: 19 April 2010 / Published: 20 April 2010 Abstract: Fibrolase is the fibrinolytic enzyme isolated from Agkistrodon contortrix contortrix (southern copperhead snake) venom. The enzyme was purified by a three-step HPLC procedure and was shown to be homogeneous by standard criteria including reverse phase HPLC, molecular sieve chromatography and SDS-PAGE. The purified enzyme is a zinc metalloproteinase containing one mole of zinc. It is composed of 203 amino acids with a blocked amino-terminus due to cyclization of the terminal Gln residue. Fibrolase shares a significant degree of homology with enzymes of the reprolysin sub-family of metalloproteinases including an active site homology of close to 100%; it is rapidly inhibited by chelating agents such as EDTA, and by alpha2-macroglobulin (). The enzyme is a direct-acting thrombolytic agent and does not rely on plasminogen for clot dissolution. Fibrolase rapidly cleaves the A()-chain of fibrinogen and the B()-chain at a slower rate; it has no activity on the -chain.
    [Show full text]
  • Guidelines on CVD During Pregnancy (TF17) - Task Force Members and Additional Contributors
    Guidelines on CVD during Pregnancy (TF17) - Task Force Members and Additional Contributors Expert Relationship Type of relationship with industry Financial declaration with Industry Blomstrom-Lundqvist Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. Carina - Medtronic : Pacemaker B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Atricure : AF ablation Borghi Claudio Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini International : ACE-inhibitors - Boheringer Ingelheim : Antihypertensive drugs - Recordati International : Antihypertensive drugs - Novartis : Antihypertensive, Heart Failure D - Research funding (departmental or institutional). - Barilla Food Company : Lactotripeptides Cifkova Renata Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular - Daiichi Sankyo : cardiovascular - MSD-SP, Boehringer Ingelheim, Bayer : cardiovascular B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular - Novartis : cardiovascular D - Research funding (departmental or institutional). - Krka Czech Republic : cardiovascular - Servier Czech Republic : cardiovascular Ferreira J Rafael No
    [Show full text]
  • Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines
    Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S.
    [Show full text]
  • 2017-001, Elio Motors, Inc. #2017-023, Taotao USA, Inc
    AGENDA LOUISIANA MOTOR VEHICLE COMMISSION 3519 12th Street Metairie, Louisiana 70002 Monday, July 10, 2017 At 10:00 a.m. Call to order. Attendance roll call. Hearings: #2017-001, Elio Motors, Inc. #2017-023, TaoTao USA, Inc. Discussion: 2017 Legislation (SB 107 - Act 45) Executive Session: Personnel Matters/Legal Advice Report by Counselors. Report by Executive Director: Reading of the Minutes of May 8, 2017. Reading of the May and June Financial Statements. Ratification of Distributor Branches License issued: DISTRIBUTOR BRANCH CITY LIC. # Kia Motors America, Inc. Plano, Texas #DB-2017-00108 Ratification of Convertor Licenses issued: CONVERTOR CITY LIC. # MAKE Louisiana Emergency Equipment LLC Eunice, Louisiana #CV-2015-00183 Louisiana Emergency Equipment Halcore Group, Inc. Jefferson, North Carolina #CV-2016-00190 AEV Trauma Hawk DBA American Emergency Vehicles Diamond Acquisition, LLC Oswego, Kansas #CV-2016-00191 Diamond Bus DBA Diamond Coach Kovatch Mobile Equipment Corp. Nesquehoning, #CV-2016-00192 KME Fire Apparatus DBA KME Fire Apparatus Pennsylvania Nite-Hawk Sweepers, LLC Kent, W ashington #CV-2017-00162 Nitehawk Sweepers McSweeney Designs, LLC Trussville, Alabama #CV-2017-00169 Ford Transit, Mercedes-Benz Sprinter Ratification of Specialty Vehicle Dealer License issued: SPECIALTY VEHICLE DEALER CITY LIC. # MAKE Louisiana Evergency Equipment LLC Eunice, Louisiana #SV-2015-00142 Louisiana Emergency Equipment Kovatch Mobile Equipment Corp. Nesquehoning, #SV-2016-00139 Conversion: KME Fire DBA KME Fire Apparatus Pennsylvania Apparatus Ratification of New Motor Vehicle Dealer Licenses issued: DEALER CITY LIC. # CAR Farmerville Motors, Inc. Farmerville, Louisiana #N-2015-00345 Buick (Passenger C ars), DBA Premier Autoplex Buick (Light Duty Trucks), C h e v r o le t ( L ig h t D u ty T r u c k s ) , C h e v r o l e t (Passenger Cars), GMC (Light Duty Trucks) This was a change in name from Farmerville Motors, Inc., 1001 Sterlington Highway, Farmerville, Louisiana to Farmerville Motors, Inc.
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • AILERON THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 AILERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents AILERON THERAPEUTICS, INC.
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax:
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Form
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the fiscal year ended December 31, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 Commission file number 000-12477 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, 91320-1799 Thousand Oaks, California (Zip Code) (Address of principal executive offices) (805) 447-1000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value; preferred share purchase rights (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Reporte Anual
    Clave de Cotización: ORBIA Fecha: 2019-12-31 [411000-AR] Datos generales - Reporte Anual Reporte Anual: Anexo N Oferta pública restringida: No Tipo de instrumento: Acciones,Deuda LP Emisora extranjera: No Mencionar si cuenta o no con aval u otra garantía, La emisión de Certificados Bursátiles se encuentra especificar la Razón o Denominación Social: avalada por las subsidiarias de la Compañía denominadas Mexichem Compuestos, S.A. de C.V., Mexichem Amanco Holding, S.A. de C.V., Mexichem Derivados, S.A. de C.V., Mexichem Resinas Vinílicas, S.A. de C.V., Mexichem Flúor, S.A. de C.V., y Mexichem Brasil Industria de Transformação Plástica Ltda. (“Mexichem Brasil”), esta última subsidiaria aval es una sociedad de nacionalidad brasileña y la totalidad de sus activos se encuentran ubicados fuera de México. De igual manera, en caso de insolvencia o quiebra de Mexichem Brasil, las reclamaciones de los Tenedores conforme a los Certificados Bursátiles quedarán sujetas a la preferencia que establezcan las leyes aplicables en la República Federal de Brasil. En su caso, detallar la dependencia parcial o total: No 1 de 209 Clave de Cotización: ORBIA Fecha: 2019-12-31 [412000-N] Portada reporte anual Orbia Advance Corporation, S.A.B. de C.V. Avenida Paseo de la Reforma 483, piso 47, Colonia Cuauhtémoc, Alcaldía Cuauhtémoc, Ciudad de México, 06500 Tel. 5366 4000 2 de 209 Clave de Cotización: ORBIA Fecha: 2019-12-31 Serie [Eje] I II Especificación de las características de los títulos en circulación [Sinopsis] Clase I II Serie Única Única Tipo Nominativa
    [Show full text]